(CIDRAP News) The National Institutes of Health (NIH) yesterday announced it has awarded contracts, which could total $150 million over 5 years, to four companies to develop broad-spectrum therapies that could help the nation respond to a bioterror attack or other public health emergency.
(CIDRAP News) – The US government recently awarded contracts totaling about $34 million to two companies for development of drugs to treat pneumonic plague, tularemia, and anthrax, three of the diseases terrorists are deemed most likely to try to exploit.
(CIDRAP News) The US government has issued about $60 million in contracts to spur development of a vaccine against tularemia, the National Institutes of Health (NIH) announced recently.
The National Institute of Allergy and Infectious Diseases (NIAID), a division of NIH, has issued two 5-year contracts for vaccine work, the agency said earlier this month. The agency also awarded $87 million in grants to build four biosafety level 3 (BSL-3) labs.
Editor's note: This story was revised shortly after publication to reflect corrections issued by the National Institute of Allergy and Infectious Diseases on May 10. The corrections pertain to the total monetary amount of the grants and to the project descriptions for XOMA (US) LLC and DVC Dynport LLC.
(CIDRAP News) Albany Medical College in Albany, N.Y., has received an $8.3 million federal grant to study pulmonary tularemia, with the main emphasis on developing a vaccine, college officials announced last week.
The grant from the National Institute of Allergy and Infectious Diseases (NIAID) will fund tularemia research at the college for 4½ years, the college said in a news release.
(CIDRAP News) Federal health officials yesterday released a 37-page report that they say demonstrates "tremendous progress" in developing countermeasures for bioterrorism through federally funded research since early 2002.
(CIDRAP News) – The US Department of Health and Human Services yesterday announced $350 million in grants for eight regional centers to lead and coordinate research on defenses against bioterrorism and emerging infectious diseases.
(CIDRAP News) The National Institute of Allergy and Infectious Diseases (NIAID) has released a 68-page report on its plan for expanding research on "Category A" bioterrorism agents: anthrax, smallpox, plague, tularemia, viral hemorrhagic fevers, and botulism.